Abatacept 250 mg
| Product Overview | |
| Generic Name | Abatacept 250 mg |
| Brand Name(s) | OHRENCIA®, Orencia® |
| Product Type | Biosimilar |
| Form | Single-Dose Vial, lyophilized powder for IV infusion |
| Strength | 250 mg/mL |
| Therapeutic Class | Selective T-cell co-stimulation modulator; inhibits T-cell activation |
| ATC Code | L04AA24 |
| Manufacturing & Regulatory | |
| Manufacturer | Dr Reddy's |
| Country | India, USA |
| GMP Compliance | WHO-GMP |
| COFEPRIS | 010.000.5820.00 |
| Free Sale Certificate | Yes, available as COPP/CPP |
| Logistics & Export | |
| MOQ | 5 units |
| Shelf Life | 24 Months |
| Storage | Refrigerate 2–8°C; do not freeze |
| Incoterms | ExW, HS/HSN 30049099 |
| Lead Time | 7 - 10 Business Days |
| Documentation | |
| Certificate of Analysis (COA) | Supplied per batch upon request |
| CTD Summary | CTD available to regulators; summary available to qualified partners |
Description
Abatacept is a biologic selective co-stimulation modulator used for moderate-to-severe rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and psoriatic arthritis, depending jurisdictional label.
